Press release
Key Trend Reshaping the Bevacizumab Biosimilars Market in 2025: Advancing Product Innovation In Bevacizumab Biosimilars Market
Bevacizumab Biosimilars
An increasing number of cancer cases is anticipated to fuel the expansion of the bevacizumab biosimilar market in the future. The term cancer incidence refers to the tally of new cancer diagnoses within a certain demographic over a specified timeframe. Bevacizumab is a biologic agent that hinders tumor angiogenesis, resulting in the potential reduction and inhibition of tumor growth and is equivalent to reference biologics in terms of effectiveness and safety when administered to patients suffering from advanced non-small cell lung cancer or metastatic colorectal cancer. For example, in October 2024, the National Health Service of the UK recorded 346,217 new instances of cancer in 2022, working out to an average of 948 cases daily. This figure is a 5% surge compared to the 329,664 diagnoses made in 2021. Cancer diagnoses also registered a 7% increase, escalating from 167,917 to 180,877 in 2022. Therefore, the escalating numbers of cancer cases directly contribute to the growth of the bevacizumab biosimilars market.
Get Your Bevacizumab Biosimilars Market Report Here:
https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report
What is the projected compound annual growth rate (CAGR) of the bevacizumab biosimilars market from 2025 to 2034, and what factors influence it?
The market for bevacizumab biosimilars has experienced robust growth in recent times. The market is anticipated to expand from $1.53 billion in 2024 to $1.66 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.2%. Factors contributing to the growth in the historical era encompass patent expiration, healthcare cost containment, a rising prevalence of cancer, increased market competition, patient access and affordability, and the acceptance of biosimilars.
It is anticipated that the bevacizumab biosimilars market will witness significant expansion in the forthcoming years. It is projected to reach a valuation of $2.27 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this growth during the projection period include increased demand for cancer treatments, skills in biosimilar development, healthcare system burdens, biosimilar regulatory frameworks, and biosimilar interchangeability. Key trends expected during this period are alliances and partnerships, regulatory progress and approvals, biosimilar development and innovation, strategies for market entry, and biosimilar lifecycle management.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp
How are the latest trends influencing the growth of the bevacizumab biosimilars market?
The bevacizumab biosimilars market is witnessing a growing trend of product innovation, with top industry leaders focused on developing unique products to consolidate their market standing. Viatris and Biocon Biologics, both US pharmaceutical companies, exemplified this trend in May 2022, when they introduced a biosimilar called Abevmy (bevacizumab), akin to Roche's Avastin (bevacizumab). Boasting approval from Health Canada for use in four oncology indications, Abevmy effectively matches the safety, efficacy, and quality of the reference biologic. This is due to its makeup as a synthesized humanized monoclonal antibody (MA), capable of binding to and neutralizing the biologic action of human vascular endothelial growth factor (VEGF).
What are the major segments of the bevacizumab biosimilars market and their role in driving growth?
The bevacizumab biosimilars market covered in this report is segmented -
1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer
Subsegments:
1) By Avastin: Original Avastin Product
2) By Mvasi: Mvasi (Amgen Biosimilar)
3) By Zirabev: Zirabev (Pfizer Biosimilar)
4) By Aybintio: Aybintio (Samsung Bioepis Biosimilar)
5) By Other Products: Additional Bevacizumab Biosimilars
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10848
Which regions are key players in the growth of the bevacizumab biosimilars market?
North America was the largest region in the bevacizumab biosimilars market in 2024. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Who are the key firms paving the way for growth in the bevacizumab biosimilars market?
Major companies operating in the bevacizumab biosimilars market include Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp
What Is Covered In The Bevacizumab Biosimilars Global Market Report?
• Market Size Forecast: Examine the bevacizumab biosimilars market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the bevacizumab biosimilars market for a structured understanding.
• Key Players Overview: Analyze major players in the bevacizumab biosimilars market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the bevacizumab biosimilars market.
• Segment Contributions: Evaluate how different segments drive overall growth in the bevacizumab biosimilars market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the bevacizumab biosimilars market.
• Industry Challenges: Identify potential risks and obstacles affecting the bevacizumab biosimilars market.
• Competitive Landscape: Review strategic developments in the bevacizumab biosimilars market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Key Trend Reshaping the Bevacizumab Biosimilars Market in 2025: Advancing Product Innovation In Bevacizumab Biosimilars Market here
News-ID: 3902980 • Views: …
More Releases from The Business Research Company
Key Factor Supporting Global Helpdesk Automation Market Development in 2025: Imp …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Helpdesk Automation Industry Market Size Be by 2025?
The market size for helpdesk automation has experienced exponential growth recently. It's projected to increase from $6.14 billion in 2024 to $8.13 billion in 2025, with a compound annual growth rate (CAGR) of 32.4%. Factors contributing to this…
Growth Of The Graph Technology Market Driven By The Expansion Of Internet of Thi …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Graph Technology Market Through 2025?
The market size for graph technology has experienced substantial growth in the recent past. Its expansion is anticipated to rise from $5.26 billion in 2024 to $6.4 billion in 2025, with a compound annual growth rate (CAGR)…
2025-2034 Generative Design Software Market Outlook: Key Drivers, Emerging Chall …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Generative Design Software Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent years, the market size for generative design software has seen a swift expansion. This growth trajectory is projected to continue, rising from $2.25 billion in 2024 to $2.66 billion in 2025, representing…
Widespread Internet Access Fuels The Growth Of Generative AI In Movies Market Em …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Generative AI In Movies Market Size Growth Forecast: What to Expect by 2025?
The market size for generative ai in movies has experienced significant expansion in the past few years. The growth is projected to increase from $0.32 billion in 2024 to $0.4 billion in 2025 with a compound…
More Releases for Biosimilar
Interchangeable Biosimilar Humira Market Share Driven by Biologic Therapy Adopti …
Interchangeable Biosimilar Humira Market
The global market for Interchangeable Biosimilar Humira was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period
View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-33I15005/Global_Interchangeable_Biosimilar_Humira_Market_Research_Report_2023
The Interchangeable Biosimilar Humira Market is experiencing significant market growth as healthcare providers and patients increasingly adopt biosimilar therapies for autoimmune and inflammatory conditions. Market trends indicate rising…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get…
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02…
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
